These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19204182)

  • 1. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy?
    Dieterle T; Meili-Butz S; Bühler K; Morandi C; John D; Buser PT; Rivier J; Vale WW; Peterson KL; Brink M
    Hypertension; 2009 Apr; 53(4):739-44. PubMed ID: 19204182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
    Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
    Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart.
    Nishikimi T; Miyata A; Horio T; Yoshihara F; Nagaya N; Takishita S; Yutani C; Matsuo H; Matsuoka H; Kangawa K
    Am J Physiol Heart Circ Physiol; 2000 Dec; 279(6):H3031-9. PubMed ID: 11087261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure.
    Meili-Butz S; Bühler K; John D; Buser P; Vale WW; Peterson KL; Brink M; Dieterle T
    Eur J Heart Fail; 2010 Aug; 12(8):797-804. PubMed ID: 20388649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of vasoactive peptide urocortin 2 on hemodynamics in spontaneous hypertensive rat and the role of L-type calcium channel and CRFR2.
    Liu C; Liu X; Yang J; Duan Y; Yao H; Li F; Zhang X
    Pharmacol Rep; 2015 Apr; 67(2):394-8. PubMed ID: 25712670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Walczewska J; Siga O; Dzieza-Grudnik A; Krolczyk J; Wizner B; Wolkow PP; Borys A; Kolton-Wroz M; Gryglewska B; Grodzicki T
    J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31443094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats.
    Abdelrahman AM; Lin Lim S; Pang CC
    Eur J Pharmacol; 2005 Mar; 510(1-2):107-11. PubMed ID: 15740730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure.
    Bale TL; Hoshijima M; Gu Y; Dalton N; Anderson KR; Lee KF; Rivier J; Chien KR; Vale WW; Peterson KL
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3697-702. PubMed ID: 14990799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure.
    Stirrat CG; Venkatasubramanian S; Pawade T; Mitchell AJ; Shah AS; Lang NN; Newby DE
    Br J Clin Pharmacol; 2016 Oct; 82(4):974-82. PubMed ID: 27275843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of long-term central and peripheral administration of urocortin, corticotropin-releasing factor, and adrenocorticotropin in sheep.
    Weisinger RS; Blair-West JR; Burns P; Denton DA; Purcell B; Vale W; Rivier J; Weisinger HS; May CN
    Endocrinology; 2004 Dec; 145(12):5598-604. PubMed ID: 15319360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.
    Coste SC; Kesterson RA; Heldwein KA; Stevens SL; Heard AD; Hollis JH; Murray SE; Hill JK; Pantely GA; Hohimer AR; Hatton DC; Phillips TJ; Finn DA; Low MJ; Rittenberg MB; Stenzel P; Stenzel-Poore MP
    Nat Genet; 2000 Apr; 24(4):403-9. PubMed ID: 10742107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urocortin and inflammation: confounding effects of hypotension on measures of inflammation.
    Torpy DJ; Webster EL; Zachman EK; Aguilera G; Chrousos GP
    Neuroimmunomodulation; 1999; 6(3):182-6. PubMed ID: 10213916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRF1 and CRF2 receptors in the bed nucleus of the stria terminalis modulate the cardiovascular responses to acute restraint stress in rats.
    Oliveira LA; Almeida J; Benini R; Crestani CC
    Pharmacol Res; 2015; 95-96():53-62. PubMed ID: 25829333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of corticotropin releasing factor (CRF), urocortin and CRF type 1 receptors in hypothalamic-hypophyseal systems under osmotic stimulation.
    Imaki T; Katsumata H; Miyata M; Naruse M; Imaki J; Minami S
    J Neuroendocrinol; 2001 Apr; 13(4):328-38. PubMed ID: 11264720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective and Vasoprotective Effects of Corticotropin-Releasing Hormone and Urocortins: Receptors and Signaling.
    Popov SV; Prokudina ES; Mukhomedzyanov AV; Naryzhnaya NV; Ma H; Zurmanova JM; der Ven PFMV; Maslov LN
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):575-584. PubMed ID: 34351805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urocortin: molecular biology and cardiovascular effects].
    Raddino R; Pedrinazzi C; Zanini G; Robba D; Bonadei I; Scarabelli TM; Cas LD
    G Ital Cardiol (Rome); 2007 Apr; 8(4):236-45. PubMed ID: 17506295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat.
    Mackay KB; Stiefel TH; Ling N; Foster AC
    Eur J Pharmacol; 2003 May; 469(1-3):111-5. PubMed ID: 12782192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-amino acid-substituted analogs of corticotropin-releasing hormone (CRH) and urocortin with selective agonist activity at CRH1 and CRH2beta receptors.
    Wei ET; Thomas HA; Christian HC; Buckingham JC; Kishimoto T
    Peptides; 1998; 19(7):1183-90. PubMed ID: 9786168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep.
    Rademaker MT; Charles CJ; Espiner EA; Fisher S; Frampton CM; Kirkpatrick CM; Lainchbury JG; Nicholls MG; Richards AM; Vale WW
    J Am Coll Cardiol; 2002 Oct; 40(8):1495-505. PubMed ID: 12392842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension.
    Yamada Y; Tsuboi K; Hattori T; Murase T; Ohtake M; Furukawa M; Ueyama J; Nishiyama A; Murohara T; Nagata K
    Hypertens Res; 2011 Jul; 34(7):809-16. PubMed ID: 21471973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.